danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics 
Welcome,         Profile    Billing    Logout  
 20 Diseases   7 Trials   7 Trials   216 News 


«1234»
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca, Celgene, danvatirsen (AZD9150) / AstraZeneca
    High-Dimensional Analysis Delineates Modulation of Myeloid and Lymphoid Compartments with STAT3 ASO and PDL-1 combination Therapy (Prince George's Exhibition Halls AB) -  Oct 2, 2019 - Abstract #SITC2019SITC_854;    
    Our data support the hypothesis that STAT3 reduction in the myeloid lineage results in activation of macrophages entering the TME and enhanced effector T cell responses in combination with checkpoint inhibition. Our ongoing work is focused on exploring the effects of STAT3 reduction in other key immune cells in which we have observed robust knockdown including Tregs, endothelial cells, and CAFs.
  • ||||||||||  cisplatin / generics
    STAT3 ASO and Cisplatin combination sensitizes protected tumor microenvironments to checkpoint-mediated therapy (Prince George's Exhibition Halls AB) -  Oct 2, 2019 - Abstract #SITC2019SITC_833;    
    Collectively, we have generated data to support the combination of low-dose chemotherapy and immunotherapy to enhance the anti-tumor immune response. As chemo-IO combinations are being explored in the clinic, it will be important to optimize dose and schedule to minimize toxicity and maximize therapeutic benefit.
  • ||||||||||  danvatirsen (AZD9150) / AstraZeneca
    Journal:  Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells. (Pubmed Central) -  Sep 18, 2019   
    STAT3 knockdown also impaired leukemic growth in vivo and led to decreased expression of MCL1 and other oncogenic genes in malignant cells. These studies demonstrate that STAT3 is an adverse prognostic factor in MDS/AML and provide a pre-clinical rationale for studies using AZD9150 in these diseases.
  • ||||||||||  danvatirsen (AZD9150) / AstraZeneca
    Clinical, Journal:  Correlation factors of 127 times pre-crisis state in patients with myasthenia gravis (Pubmed Central) -  May 8, 2019   
    Dyspnea indicates the occurrence of the Pre-Crisis State of MG. In order to significantly reduce the morbidity of myasthenia crisis, the bulbar-muscle weakness, the increased blood PCO(2), expectoration weakness, sleep disorders, infection & fever and excess oropharyngeal secretions should be treated timely.
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca
    Enrollment open, Combination therapy:  NeoCOAST: Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov) -  Mar 22, 2019   
    P2,  N=160, Recruiting, 
    In order to significantly reduce the morbidity of myasthenia crisis, the bulbar-muscle weakness, the increased blood PCO(2), expectoration weakness, sleep disorders, infection & fever and excess oropharyngeal secretions should be treated timely. Not yet recruiting --> Recruiting
  • ||||||||||  Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca, danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
    Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, PD(L)-1 Biomarker, IO biomarker:  MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023) (clinicaltrials.gov) -  Feb 27, 2019   
    P1b,  N=32, Completed, 
    Trial completion date: Oct 2019 --> Apr 2020 | Trial primary completion date: Oct 2019 --> Apr 2020 Active, not recruiting --> Completed | Trial completion date: Nov 2023 --> Feb 2019 | Trial primary completion date: Nov 2023 --> Feb 2019
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca, danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
    Enrollment closed, Combination therapy, Monotherapy, Metastases:  Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies (clinicaltrials.gov) -  Oct 18, 2018   
    P1,  N=11, Active, not recruiting, 
    N=200 --> 260 | Trial completion date: Nov 2020 --> Jul 2021 | Trial primary completion date: Nov 2020 --> Jul 2021 Recruiting --> Active, not recruiting
  • ||||||||||  Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca, danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
    Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, PD(L)-1 Biomarker, IO biomarker:  MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023) (clinicaltrials.gov) -  Mar 15, 2018   
    P1b,  N=207, Recruiting, 
    Trial completion date: Apr 2019 --> Nov 2019 | Trial primary completion date: Apr 2019 --> Nov 2019 Trial completion date: Nov 2022 --> Sep 2023 | Trial primary completion date: Aug 2022 --> Jun 2023
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca, danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy, Monotherapy, Metastases:  Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies (clinicaltrials.gov) -  Feb 13, 2018   
    P1,  N=12, Recruiting, 
    N=257 --> 465 | Trial primary completion date: Aug 2018 --> Oct 2019 | Trial completion date: Aug 2018 --> Oct 2019 Not yet recruiting --> Recruiting | Trial completion date: Nov 2018 --> Dec 2018 | Initiation date: Jan 2018 --> Jan 2018 | Trial primary completion date: Nov 2018 --> Dec 2018
  • ||||||||||  danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
    Trial primary completion date:  AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites (clinicaltrials.gov) -  Feb 9, 2017   
    P2,  N=1, Terminated, 
    Not yet recruiting --> Recruiting Trial primary completion date: Jan 2017 --> Apr 2016